Friday, July 18, 2025 7/18/2025

Sex-specific Impact of Prenatal Opioids on Brain Reward Signaling and Neonatal Feeding Regulation

Award Number: K23DA056847
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 03/01/2023
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Sex-specific Impact of Prenatal Opioids on Brain Reward Signaling and Neonatal Feeding Regulation - Project Summary/Abstract: Although Neonatal Abstinence Syndrome (NAS) is an urgent public health priority, the diagnosis and management of NAS remains challenging. This is primarily due to the multifactorial nature of NAS and the highly subjective measures to assess this condition. Males and females with NAS have distinct risk profiles, yet within the current paradigm they are managed uniformly. The limited understanding of long-term outcomes further compounds the problem and predisposes this population to a myriad of health issues. To address these knowledge gaps, the current proposal expands upon the molecular and behavioral data from our K12-funded pilot study to better understand the impact of prenatal opioid exposure. An early sign of withdrawal in opioid- exposed neonates is difficulty feeding followed by hyperphagia, which often precedes severe NAS and the need for pharmacotherapy. Using saliva collected immediately after birth, we showed higher expression of a key reward gene (DRD2) in opioid-exposed males compared to females. The expression of DRD2 also correlated with the caloric intake in opioid-exposed males who later developed severe NAS and required pharmacotherapy. These transcriptomic-behavioral data indicate that prenatal opioid exposure dysregulates brain reward signaling in a sex-specific manner, resulting in hyperphagia as a reward-seeking behavior that offsets the acute loss of opioids. Furthermore, opioid-exposed neonates have heightened expression of inflammatory genes (IL6, MCP1) that correlate with the expression of DRD2, particularly in females. Expanding on these preliminary results, the current proposal will examine if prenatal opioids dysregulate brain reward signaling and modulate pro-inflammatory pathways with increased sex-specific risks for hyperphagia and associated long-term cardiometabolic disorders. Our overarching goal is to understand changes in sex-specific reward and inflammatory gene expression in opioid-exposed neonates throughout the first year of life. The hypothesis will be tested in two aims: 1) Identify sex-specific effects of prenatal opioids on reward signaling and inflammation, 2) Evaluate effects of prenatal opioids on risk for subsequent cardiometabolic disorders. We will collect serial saliva samples from 56 opioid-exposed and 56 sex- and age-matched non-exposed neonates during the initial hospitalization and then in a subset of infants post hospital discharge up to 1 year of age to evaluate the expression of reward and inflammation genes. Early cardiometabolic risk will be assessed using serum lipid panels at 1 year of age, along with growth and nutritional data. Results will be analyzed by sex. The impact of this proposed project lies in the potential to advance the field with a more comprehensive understanding of the sex-specific impact of prenatal opioid exposure on the developing brain through non- invasive molecular analyses, enabling personalized medicine and longitudinal health monitoring.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $191,160 )
2025	2025	TUFTS MEDICAL CENTER PARENT, INC.	800 WASHINGTON ST	BOSTON	MA	02111	SUFFOLK	USA	Drug Use and Addiction Research Programs	000	3	3/24/2025	NON-COMPETING CONTINUATION	$191,160
														Subtotal = $191,160

Issue Date FY: 2024 ( Subtotal = $191,160 )
2024	2024	TUFTS MEDICAL CENTER PARENT, INC.	800 WASHINGTON ST	BOSTON	MA	02111	SUFFOLK	USA	Drug Use and Addiction Research Programs	000	2	2/23/2024	NON-COMPETING CONTINUATION	$191,160
														Subtotal = $191,160

Issue Date FY: 2023 ( Subtotal = $191,160 )
2023	2023	TUFTS MEDICAL CENTER, INC.	800 WASHINGTON ST	BOSTON	MA	02111	SUFFOLK	USA	Drug Use and Addiction Research Programs	000	1	2/17/2023	NEW	$191,160
														Subtotal = $191,160

Grand Total All Awards = $573,480

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Sex-specific Impact of Prenatal Opioids on Brain Reward Signaling and Neonatal Feeding Regulation

Award Number: K23DA056847

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 03/01/2023

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer